Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 151-166

  Rodrigueza, Wendi V ^a   Woolliscroft, Michael J ^a   Ebrahim, Abdul Shukkur ^b   Forgey, Robert ^a   McGovren, Patrick J ^a   Endert, Gerold ^c   Wagner, Andreas ^d   Holewa, Danielle ^a   Aboukameel, Amro ^b   Gill, Richard D ^a   Bisgaier, Charles L ^a   Messmann, Richard A ^a   Whitehead, Christopher E ^a   Izbicka, Elzbieta ^e   Streeper, Robert ^e   Wick, Michael C ^f   Stiegler, Gabriela ^d   Stein, C A ^g   Monsma, David ^h   Webb, Craig ^h   Sooch, Mina P ^a   Panzner, Steffen ^c   Mohammad, Ramzi ^b   Goodwin, Neal C ^a   Al Katib, Ayad ^b   more..

^a ProNAi Therapeutics Inc   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Novosom AG   (Germany)

^d Polymun Scientific GmbH   (Austria)

^e BTNS LLC   (United States)

^f South Texas Accelerated Research Therapeutics (START)   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Anticancer agent; BCL 2; Deoxyribonucleic acid interference; DNAi ; Liposomes; PNT2258

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 6; LIPOSOME; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; OLIGONUCLEOTIDE; PNT 100; PNT 2258; PROTEIN BCL 2; RANTES; RITUXIMAB; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA INTERFERENCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SCREENING; DRUG TISSUE LEVEL; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; LIPID COMPOSITION; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VOLUME;

5' FLANKING REGION; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, ANTISENSE; DNA, SINGLE-STRANDED; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; GENE SILENCING; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PHARMACEUTICAL VEHICLES; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903821034     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2476-y     Document Type: Article

References (51)

1. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6
2. Davids MS, Letai A (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 30:3127-3135
3. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S et al (1988) Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123-131
4. Heckman CA, Mehew JW, Boxer LM (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898-3908 (Pubitemid 34620858)
5. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM (1987) DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc Natl Acad Sci USA 84:1329-1331 (Pubitemid 17027346)
6. Yonetani N, Ueda C, Akasaka T, Nishikori M, Uchiyama T, Ohno H (2001) Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5′ region of BCL-2 in B-cell tumors. J Cancer Res 92:933-940 (Pubitemid 32970433)
7. Pickering BF, Yu D, Van Dyke MW (2011) Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNA s 15a and 16. J Biol Chem 286:44095-44103
8. Iorio MV, Croce CM (2012) MicroRNA involvement in human cancer. EMBO Mol Med 4:143-159
9. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17:315-324
10. Thomas S, Quinn BA, Das SK, Dash R, Emdad L et al (2013) Targeting the Bcl-2 family for cancer therapy. Exp Opin Cancer Targets 17:61-75
11. Blackledge NP, Klose RJ (2011) CpG island chromatin: a platform for gene regulation. Epigenetics 6:147-152
12. Deaton AM, Bird A (2011) CpG islands and regulation of transcription. Genes Dev 25:1010-1022
13. Thurman RE, Rynes E, Humbert R, Vierstra H, Maurano MT (2012) The accessible chromatin landscape of the human genome. Nature 489:75-82
14. Maston GA et al (2006) Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet 7:29-59 (Pubitemid 44627921)
15. Sabo PJ, Kuehn MS, Thurman R, Johnson BE, Johnson BE et al (2006) Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 3:511-518 (Pubitemid 43941768)
16. Brazda V, Laister RC, Jagelska EB, Arrowsmith C (2011) Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol Biol 12:33-48
17. Kendrick S, Hurley LH (2010) The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem 82(8):1609-1621
18. Brooks TA, Hurley LH (2010) Targeting MYC Expression through G-Quadruplexes. Genes Cancer 1:641-649
19. Balasubramanian S, Hurley LH, Neidle S (2011) Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov 10:261-275
20. Young SL, Korsmeyer SJ (1993) A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 13:3686-3697
21. Chen HM, Boxer LM (1995) P1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 15:3840-3847
22. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131-3135 (Pubitemid 24208916)
23. Duan H, Xiang H, Ma L, Boxer LM (2008) Functional Longrange Interactions of the IgH 3′ Enhancers with the bcl-2 Promoter Region in t(14;18) Lymphoma Cell. Oncogene 27:6720-6728
24. Siepi E, Lutz S, Meyer S, Panzner S (2011) An ion switch regulates fusion of charged membranes. Biophys J 100:2412-2421
25. Arranz A, Reinsch C, Papadakis KA, Dieckmann A, Rauchhaus U et al (2013) Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release 165:163-172
26. Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V et al (2009) Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 60:994-1005
27. Tolcher A, Rodrigueza WV, Rasco DW et al (2013) A Phase 1 Study of the BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013 (in press)
28. Wagner A, Vorauer-Uhl K, Kreismayr G, Katinger H (2002) The crossflow injection technique-an improvement of the ethanol injection method. J Liposome Res 12(3):259-270 (Pubitemid 35403645)
29. Wagner A, Vorauer-Uhl K, Katinger H (2002) Liposome produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 54:213-219 (Pubitemid 34919396)
30. Corbett TH, Roberts BJ, Leopold WR, Peckman JC, Wilkoff LJ et al (1984) Induction and Chemotherapeutic Response of Two Transplantable Ductal Adenocarcinomas of the Pancreas in C57BL/6 Mice. Cancer Res 44:717-726 (Pubitemid 14184610)
31. Mohammad RM, Mohamed AN, Smith MR, Jawadi N, Al-Katib A (1993) A unique EBV- negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;8) and t(8;11). Cancer Genetics Cytogenetics 70:62-67 (Pubitemid 23333303)
32. Dias N, Stein C (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347-355
33. Kawasaki H, Taira K (2004) Induction of DNA methylation and gene silencing by short interfering RNA s in human cells. Nature 431:211-217 (Pubitemid 39243476)
34. Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C et al (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10:7244-7251 (Pubitemid 39487711)
35. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ (2005) Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56:46-54 (Pubitemid 41201755)
36. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT (2002) Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in Murine Models. J Drug Target 10:539-548 (Pubitemid 36124352)
37. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN (1998) The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393-1403 (Pubitemid 28265221)
38. Janowski BA, Huffman KE, Schwartz JC, Ram R, Hardy D et al (2005) Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNA s. Nat Chem Biol 1:216-222
39. Liu CM, Lui DP, Liang CC (2002) Oligonucleotide-mediated gene repair at DNA level: the potential applications for gene therapy. J Mol Med 80:620-628
40. Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discovery 11:125-140
41. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D et al (2010) Review: status report on RNA i therapeutics. Silence 1:14-26
42. Deleavey GF, Damha MJ (2012) Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 19:937-954
43. Chonn A, Cullis PR, Devine DV (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146:4234-4241
44. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M et al (2010) Targeted Delivery of RNA i Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. Mol Ther 18:1357-1364
45. Hope MJ, Rodrigueza WV (1995) Membrane lipids and model membrane systems. In: Severs N, Shotton D (eds) Rapid freezing, freeze fracture and deep etching (techniques in modern biomedical microscopy). Wiley, New York, pp 235-253
46. Rodrigueza WV, Pritchard PH, Hope MJ (1993) Influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim Biophys Acta 1153:9-19 (Pubitemid 23348978)
47. Rodrigueza WV, Mazany KE, Essenburg AE, Pape ME, Bisgaier CL, Williams K (1997) Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: implications for the treatment of atherosclerosis. Arterioscler Thromb Vasc Biol 17:2132-2139 (Pubitemid 28060606)
48. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16-20
49. Maurer N, Fenske DB, Cullis PR (2001) Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1(6):923-947
50. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM et al (2011) BCL-2 Predicts Survival in Germinal Center B-cell-like DLBCL Treated with CHOP-like Therapy and Rituximab. Clin Cancer Res 17:7785-7795
51. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A (2012) Immunohistochemical Double Hit Score is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophsphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 30:3460-3467